AACR 2019

March 29–April 3, 2019 | Georgia World Congress Center, Atlanta, GA

AACR 2019

March 29–April 3, 2019

Georgia World Congress Center, Atlanta, GA


Bringing new insights to life™

Empowering the immune system to recognize and eliminate tumors has tremendous potential to change the way cancer is treated and eventually cured. At Fluidigm, we enable comprehensive cellular profiling of the immune system and the tumor microenvironment with proven mass cytometry and microfluidics technologies.

Whether you seek to target new biomarkers and pathways or to optimize the effectiveness of checkpoint inhibitors, CAR T cells or cancer vaccines, Fluidigm can help you gain new insights to reach your next research breakthrough.

Visit Fluidigm at Booth 1523

Exhibit Dates and Hours:

Sunday, March 31 1:00–5:00 pm
Monday, April 1 9:00 am–5:00 pm
Tuesday, April 2 9:00 am–5:00 pm
Wednesday, April 3 9:00 am–12:00 pm

In-booth Presentations

Join us in Booth 1523 for 15-minute presentations introducing new multi-omic products to help you advance your cancer research and investigation of the tumor microenvironment. Speak with our experts and get your questions answered.

Immune Profiling
Introducing the New Standard in Immune Profiling

Get a first look at an exciting new product providing a sample-to-answer solution ideal for immune monitoring studies in clinical and translational research.

Sunday, March 31 2:15 pm
Monday, April 1 12:15 pm and 2:15 pm
Tuesday, April 2 12:45 pm and 2:45 pm
Wednesday, April 3 10:45 am

Tumor Profiling
Coming Soon: A Flexible, Comprehensive Workflow for Solid Tumor and Gene Fusions NGS Library Prep

Learn about how our solid tumor and RNA fusions NGS library prep assays in development can help empower your research with simultaneous, automated analysis of SNVs, CNVs, indels and gene fusions in a single workflow.

Sunday, March 31 2:45 pm
Monday, April 1 12:45 pm and 2:45 pm
Tuesday, April 2 12:15 pm and 2:15 pm
Wednesday, April 3 10:15 am

Featured Products

Come visit our booth and learn how you can deeply profile tumors and the tumor immune response from every angle.

Hyperion™ Imaging System

Comprehensively interrogate complex cellular phenotypes and their interrelationships in the context of the tumor microenvironment with Imaging Mass Cytometry™.

Hyperion Imaging System

Helios™, a CyTOF® system

Deeply profile immune and tumor cell populations for phenotype and function, all in a single tube.

Helios, a CyTOF System

Biomark™ HD

Reveal the molecular signatures of tumor immune response using the Advanta™ IO Gene Expression Assay on the Biomark HD.

Biomark HD


Achieve significant cost savings and reduced hands-on time with automated NGS library prep.



Reveal the diversity of immune cell subpopulations and T cell receptor clonotypes in health and disease states at single-cell resolution.


View and discuss Fluidigm posters with the authors




Poster Number


Sunday, March 31 | 1:00-5:00 pm
Genomics Development of a comprehensive gene fusion NGS panel using an integrated microfluidic circuit enabling highly efficient multiplex PCR enrichment Thomas J. Goralski, PhD 33/745 Cancer Genomics 1
Monday, April 1 | 8:00 am-12:00 pm
Mass Cytometry A robust human immune profiling assay using CyTOF® technology and automated data analysis software Stephen Li, PhD 31/1667 Laboratory and Computational Methods for Cancer Analysis
Wednesday, April 3 | 8:00 am-12:00 pm
Genomics Full-length mRNA transcriptome analysis of matched circulating tumor and immune cells from breast cancer subjects Naveen Ramalingam, PhD 42/LB-326 Late-Breaking Research: Tumor Biology 3

Attend presentations and view posters featuring Fluidigm technology





Session Location

Sunday, March 31 | Mass Cytometry
7:00–8:00 am High-Dimensional Single-Cell Mass Cytometry in Translational Cancer Research Kara L. Davis, DO
Stanford University
High-Dimensional Single-Cell Mass Cytometry in Translational Cancer Research
Room B304
3:35–3:50 pm Characterization of murine mammary epithelial populations throughout development and in premalignant tissue via mass cytometry Gary Gray, PhD
Harvard Medical School
Novel Approaches to Understand Cancer Stem Cells
Room A404
Monday, April 1 | Mass Cytometry
3:50–4:05 pm Lymph node colonization promotes distant tumor metastasis through the induction of systemic immune tolerance Nathan E. Reticker-Flynn, PhD
Harvard Medical School
Novel Approaches to Understand Cancer Stem Cells
Room A404
Tuesday, April 2 | Mass Cytometry
3:00–5:00 pm Effector B cells and tertiary lymphoid structures predict response to immune checkpoint blockade in solid tumors Sangeetha M. Reddy, MD
MD Anderson Cancer Center
Immune Microenvironment
Room A411
Wednesday, April 3 | Imaging Mass Cytometry
10:50–11:15 am A large-scale single-cell atlas of human breast cancer links tumor ecosystems to poor prognosis and immunosuppression Bernd Bodenmiller, PhD
University of Zurich
AACR-Bayard D. Clarkson Symposium: Single-Cell Analysis of Tumor Heterogeneity
Hall A

Poster sessions




Poster Number

Session Name

Sunday, March 31 | 1:00–5:00 pm
Mass Cytometry Synthetic essentiality of chromatin remodeling factor CHD1 in PTEN deficient cancer Di Zhao, PhD
MD Anderson Cancer Center
4/95 Developmental Phenotypes and Molecular Imaging
Mass Cytometry Single-cell RNA sequencing reveals compromised immune microenvironment in precursor stages of multiple myeloma Nicholas Haradhvala
Broad Institute
6/139 Gene Expression in the Tumor Microenvironment
Mass Cytometry High-dimensional profiling of the systemic immune response informs on optimal sequencing of radiotherapy (RT) and immune checkpoint blockade (ICB) Kevin L.M. Chua
National Cancer Centre Singapore
22/527 Radiation-Induced Immunomodulation
Monday, April 1 | 8:00 am–12:00 pm
Imaging Mass Cytometry Revisiting immune exhaustion in Hodgkin’s lymphoma Anthony Colombo
University of Southern California, Los Angeles
9/1189 Tumor-Immune Interactions
Mass Cytometry The immune atlas and chemokine profile of giant cell tumor of bone Binghao Li, MBBS
The Second Affiliated Hospital of Zhejiang University School of Medicine
23/1486 Cellular Interactions in the Tumor Microenvironment
Mass Cytometry Identification of immunotherapy resistance mechanisms within tumor microenvironment in a mouse model of oral squamous cell carcinoma Liye Zhou
Dana-Farber Cancer Institute
24/1509 Suppressive Myeloid Cells
Mass Cytometry The CD30/CD16A bispecific innate immune cell engager AFM13 elicits heterogeneous single-cell NK cell responses and effectively triggers memory-like (ML) NK cells Nancy Marin, PhD
Washington University School of Medicine
25/1546 Therapeutic Antibodies 2
Mass Cytometry TLR7/8 immune-stimulating antibody conjugates elicit robust myeloid activation leading to enhanced effector function and anti-tumor immunity in pre-clinical models Shelley Ackerman, PhD
Bolt Biotherapeutics
25/1559 Therapeutic Antibodies 2
Monday, April 1 | 1:00–5:00 pm
Mass Cytometry AXL inhibitor TP-0903 attenuates AXL-TGFbeta Hippo signaling axis in lung adenocarcinoma cells Josephine Amalia Taverna, MD
University of Texas Health Science Center at San Antonio
15/2193 Tyrosine Kinase and Phosphatase Inhibitors 2
Mass Cytometry Role of midkine in molecular targeted therapy to TIP1 for lung cancer treatment Vaishali Kapoor, PhD
Washington University School of Medicine
25/2389 Therapeutic Antibodies 3
Mass Cytometry A comprehensive genomics platform for precision immunotherapy: simultaneously characterizing the tumor and tumor microenvironment from a single FFPE sample Richard O. Chen, MD
33/2512 Cancer Genomics 3
Tuesday, April 2 | 8:00 am–12:00 pm
Imaging Mass Cytometry Highly multiplexed Imaging Mass Cytometry™ reveals immune cell composition and spatial heterogeneity in diffuse large B cell lymphoma associated with treatment outcome Monirath Hav, MD, PhD
University of Southern California
3/2789 Immune Cells in the Tumor Microenvironment 2
Mass Cytometry Dynamics of T cell checkpoint receptor profiles during melanoma progression Jarem Edwards
University of Sydney
24/3246 Immune Checkpoints 1
Tuesday, April 2 | 1:00–5:00 pm
Mass Cytometry Mapping the osteogenic lineage and identification of the cell of origin of osteosarcoma through high-dimensional analysis Yifei Wang, MD
MD Anderson Cancer Center
2/3655 Biology and Signaling in Pediatric Cancer
Mass Cytometry Mass cytometry approaches to biomarker discovery via high-dimensional antigen-specific T cell identification and profiling Mathew Cobbett, MBA
immunoSCAPE, Singapore
22/4054 Biomarkers and Immune Monitoring
Mass Cytometry Late-differentiated effector neoantigen-specific CD8+ T cells are enriched in non-small cell lung cancer patients responding to atezolizumab treatment Mahesh Yadav, PhD
Genentech, South San Francisco
22/4055 Biomarkers and Immune Monitoring
Mass Cytometry Single cell immune profiling of patients with advanced biliary cancers treated with combination checkpoint inhibition and GM-CSF reveals diverse T cell and myeloid cell mechanisms of action Bridget Keenan, MD, PhD
University of California San Francisco
22/4063 Biomarkers and Immune Monitoring
Mass Cytometry DDR2 inhibition enhances response to anti-PD-1 immunotherapy Megan Tu, PhD
University of Colorado Anschutz Medical Campus
23/4085 Combination Immunotherapies 3
Mass Cytometry Is biomarker-driven precision medicine possible by using high-dimensional augmented intelligence-assisted analysis of cancer immune responses? Carsten Krieg, PhD
Medical University of South Carolina
28/4225 Clinical Prevention, Early Detection, and Interception 2
Wednesday, April 3 | 8:00 am–12:00 pm
Genomics Subclone-specific evolution of tumor phenotypes: a framework to study subclone-specific gene expression from a combination of bulk DNA and single cell RNA sequencing data Yi Qiao, PhD
University of Utah
9/4689 Tumor Evolution and Heterogeneity 3
Mass Cytometry Single cell mass cytometry analysis distinguishes indolent from aggressive lung adenocarcinomas Maria-Fernanda Senosain
Vanderbilt University
9/4701 Tumor Evolution and Heterogeneity 3
Imaging Mass Cytometry Investigating triple negative breast cancer phenotypic heterogeneity of human and patient-derived xenograft samples using Imaging Mass Cytometry™ Amanda Rinkenbaugh, PhD
MD Anderson Cancer Center
9/4708 Tumor Evolution and Heterogeneity 3
Mass Cytometry Blockade of EphB4-ephrin-B2 interaction remodels the tumor immune microenvironment in head and neck cancers Shilpa Bhatia, PhD
University of Colorado Anschutz Medical Campus
25/5035 Tumor Immune Microenvironment
Mass Cytometry Single cell RNA sequencing reveals altered natural killer-like, effector CD8+ T lymphocytes in smokers Suzanne N. Martos, PhD
National Institute of Health
26/5057 Influences on Cancer Risk and Outcomes

Social Media

Can’t make it to all of the sessions? Follow @fluidigm with #AACR2019 and like us on Facebook for scientific and event updates.

For more information, visit the AACR 2019 event website.

For Research Use Only. Not for use in diagnostic procedures.